Table 1.

Patient demographics and clinical characteristics

CharacteristicAll patients (N = 32)
Sex, M/F (%) 14/18 (44/56) 
Age at MM diagnosis, median (range), y 59 (46-77) 
Age at ALL/BALLP diagnosis, median (range), y 65 (50-86) 
Time from MM to ALL/BALLLP, median (range), y 5.5 (0.6-11.7) 
Length of lenalidomide exposure, median (range), mo 41.8 (1.8-114.1) 
MM characteristics, n (%)  
IgG heavy chain 19 (59) 
IgA heavy chain 8 (25) 
Unknown heavy chain 3 (9) 
Light chain only MM 2 (6) 
κ light chain 19 (59) 
λ light chain 12 (38) 
Unknown light chain 1 (3) 
MM presentation, n (%)  
Hypercalcemia 2 (6) 
Renal insufficiency 5 (16) 
Anemia 9 (2) 
Bony lesions 25 (7) 
CRAB criteria status unknown 3 (9) 
Leptomeningeal disease 1 (3) 
ALL/BALLLP lineage and presentation, n (%)  
T-cell 
B-cell 32 (100) 
Overt B-ALL at diagnosis 29 (91) 
BALLLP at diagnosis 3 (9) 
BCR::ABL-positive 1 (3) 
BCR::ABL-negative 31 (91) 
CD10 expression 29 (91) 
CD20 expression 18 (56) 
Low hypodiploidy  8 (31)  
11q23 rearrangement  2 (8)  
CharacteristicAll patients (N = 32)
Sex, M/F (%) 14/18 (44/56) 
Age at MM diagnosis, median (range), y 59 (46-77) 
Age at ALL/BALLP diagnosis, median (range), y 65 (50-86) 
Time from MM to ALL/BALLLP, median (range), y 5.5 (0.6-11.7) 
Length of lenalidomide exposure, median (range), mo 41.8 (1.8-114.1) 
MM characteristics, n (%)  
IgG heavy chain 19 (59) 
IgA heavy chain 8 (25) 
Unknown heavy chain 3 (9) 
Light chain only MM 2 (6) 
κ light chain 19 (59) 
λ light chain 12 (38) 
Unknown light chain 1 (3) 
MM presentation, n (%)  
Hypercalcemia 2 (6) 
Renal insufficiency 5 (16) 
Anemia 9 (2) 
Bony lesions 25 (7) 
CRAB criteria status unknown 3 (9) 
Leptomeningeal disease 1 (3) 
ALL/BALLLP lineage and presentation, n (%)  
T-cell 
B-cell 32 (100) 
Overt B-ALL at diagnosis 29 (91) 
BALLLP at diagnosis 3 (9) 
BCR::ABL-positive 1 (3) 
BCR::ABL-negative 31 (91) 
CD10 expression 29 (91) 
CD20 expression 18 (56) 
Low hypodiploidy  8 (31)  
11q23 rearrangement  2 (8)  

F, female; M, male.

Includes patients with low hypodiploid features by traditional karyotyping (n = 5) or by FISH (n = 3).

Because low disease burden and/or lack of comprehensive cytogenetic data for 6 patients in the series, total evaluable patients here are considered as 26 rather than 32.

Refer to Discussion in the manuscript; possible but not definite in 1 of 2 patients.

Close Modal

or Create an Account

Close Modal
Close Modal